A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

10.8K views

⸱

DOI:

10.3791/50244

⸱

May 30th, 2013

 ,  , 

In This Article

Summary

CD4+ Regulatory T cells are potent immune-modulators and serve important functions in immune homeostasis. The paucity of these cells in peripheral blood makes functional studies challenging, specifically in the context of HIV-1-infection. We here describe a method to isolate and expand functional CD4+ Tregs from peripheral blood from HIV-1-infected individuals.

Abstract

CD4+ Regulatory T cells (Tregs) are potent immune modulators and serve an important function in human immune homeostasis. Depletion of Tregs has led to measurable increases in antigen-specific T cell responses in vaccine settings for cancer and infectious pathogens. However, their role in HIV-1 immuno-pathogenesis remains controversial, as they could either serve to suppress deleterious HIV-1-associated immune activation and thus slow HIV-1 disease progression or alternatively suppress HIV-1-specific immunity and thereby promote virus spread. Understanding and modulating Treg function in the context of HIV-1 could lead to potential new strategies for immunotherapy or HIV vaccines. However, important open questions remain on their role in the context of HIV-1 infection, which needs to be carefully studied.

Representing roughly 5% of human CD4+ T cells in the peripheral blood, studying the Treg population has proven to be difficult, especially in HIV-1 infected individuals where HIV-1-associated CD4 T cell and with that Treg depletion occurs. The characterization of regulatory T cells in individuals with advanced HIV-1 disease or tissue samples, for which only very small biological samples can be obtained, is therefore extremely challenging. We propose a technical solution to overcome these limitations using isolation and expansion of Tregs from HIV-1-positive individuals.

Here we describe an easy and robust method to successfully expand Tregs isolated from HIV-1-infected individuals in vitro. Flow-sorted CD3+CD4+CD25+CD127low Tregs were stimulated with anti-CD3/anti-CD28 coated beads and cultured in the presence of IL-2. The expanded Tregs expressed high levels of FOXP3, CTLA4 and HELIOS compared to conventional T cells and were shown to be highly suppressive. Easier access to large numbers of Tregs will allow researchers to address important questions concerning their role in HIV-1 immunopathogenesis. We believe answering these questions may provide useful insight for the development of an effective HIV-1 vaccine.

Introduction

With more than 34 million individuals living with HIV/AIDS worldwide and an estimated 2.5 million people newly infected in 2011, the need for an effective HIV vaccine to curb the worldwide HIV epidemic remains paramount. However, despite three decades of intense research efforts, the HIV-1 vaccine efficacy trials to date have resulted in only modest protection 1-3 and the correlates of protective immunity remain poorly understood. Elucidating the nature of the immune response needed for protection is essential for the strategic design of an effective HIV-1 vaccine and other immunotherapeutic strategies targeting HIV-1 infection.

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Regulatory T cell isolation from HIV-1 Positive Blood

  1. Carefully transfer blood, collected in ACD tubes, into a 50 ml conical tube for a final volume of 15 ml blood per tube.
  2. Add 25 μl/ml of blood of RosetteSep Human CD4+ T Cell Enrichment Cocktail, mix carefully and incubate 20 min at room temperature.
  3. Add 15 ml of PBS/2% FBS to the blood and mix carefully. Layer the diluted blood sample on top of 15 ml of Histopaque at room temperature in a 50 ml conical tube. Spin the conical tube for 20 min at 1,200 x g with a slow start and no brakes.
  4. Transfer the CD4+ T cell enriched PBMC layer in a new 50 ml conical....

Access restricted. Please log in or start a trial to view this content.

Results

The expression of interleukin 2 receptor (CD25) and the interleukin 7 receptor (CD127) have been described as reliable surface markers to identify functional Treg populations 13 and have been shown to correlate with CD4+CD25+FOXP3+ Tregs 9,12. Figure 1 represents the gating strategy used to flow-sort single CD3+CD4+CD25+CD127low Tregs from PBMC isolated from an HIV-1-positive individual. The CD25/CD127 anti.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Using the protocol described above, Tregs can be successfully isolated and expanded from HIV-1-infected individuals in vitro. Expanded Tregs express high levels of FOXP3, CTLA4 and HELIOS, are highly suppressive and display a highly demethylated Treg-Specific Demethylation Region (TSDR) locus of the FOXP3 gene (data not shown) 15, suggesting true origin from the regulatory T cell lineage, as opposed to activation-induced transient FOXP3 upregulation. Deep sequencing demonstrated that the TCR repertoir.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

This work was supported in part by research funding from the Elisabeth Glaser Pediatric AIDS Foundation (Pediatric HIV Vaccine Program Award MV-00-9-900-1429-0-00 to MMA), MGH/ECOR (Physician Scientist Development Award to MMA), NIH NIAID (KO8219 AI074405 and AI074405-03S1 to MMA), and the Harvard University Center for AIDS Research (CFAR), an NIH funded program (P30 AI060354) which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR. These studies were furthermore supported by the Bill & Melinda Gates Foundation and the Terry and Susan Ragon Foundation.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
RosetteSep Human CD4+ T Cell Enrichment CocktailStemcells technologies15062
PBSSigmaD8537
FBSSigmaF4135
HistopaqueSigmaH8889
Anti-CD3-PECy7BD Pharmingen557851
Anti-CD4-FITCeBioscience11-0049-42
Anti-CD25-APCeBioscience17-0259-42
Anti-CD127-PEBD Pharmingen557938
Round-Bottom tube with 35 μm a nylon meshBD Falcon352235
X-VIVO 15Lonza04-418Q
Penicillin/StreptomycinMediatech30-001-Cl
Human SerumGemini Bio-Products100-512
Human T-activator CD3/CD28Life Technologies111.31D
IL-2NIH Aids Research Reference Reagent Program136
LIVE/DEAD Fixable Violet Dead Cell Stain KitLife technologiesL34955
Anti-CD4-qdot-655Life TechnologiesQ10007
Anti-CD25-PECy5eBiosciences15-0259-42
Foxp3 / Transcription Factor Staining Buffer SeteBiosciences00-5523-00
Anti-FOXP3-PEeBiosciences12-4776-42
Anti-HELIOS-FITCBiolegend137204
Anti-CTLA4-APCBD Pharmingen555855
CellTrace Violet Cell Proliferation KitLife TechnologiesC34557
Vybrant CFDA SE Cell Tracer KitLife TechnologiesV12883
HEPESMediatech25-060-Cl
Treg Suppression inspectorMiltenyi Biotec130-092-909
Anti-CD4-APCBD Pharmingen340443
Anti-CD8-AF700BD Pharmingen557945
RPMI 1640SigmaR0883
GlutamineMediatech25-002-Cl
Materials
BD Vacutainer Blood Collection Tube w/ ACID CITRATE DEXTROSE (ACD)Becton, Dickinson and Company (BD)364606
FACSAria IIu Cell SorterBD Biosciences-
LSR II Flow CytometerBD Biosciences-
FlowJoTree Starv887

References

  1. Rerks-Ngarm, S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
  2. Buchbinder, S. P., et al. Eff....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

HIV-1 InfectionFlow CytometryCell SortingT Cell ExpansionImmunosuppression AssayFOXP3 ExpressionCTLA4 MarkerHELIOS MarkerAnti-CD3/CD28 Beads